Two pharmaceutical companies on Wall Street have what it takes to maintain consistent and growing dividends: Amgen (AMGN) and AbbVie (ABBV). Both companies have excellent track records, solid underlying businesses, and a strong pipeline of growth drivers.
Amgen, a biotech giant, has increased its dividend payouts regularly since 2011, growing them by 750% in that period. The company’s revenue grew 19% year over year in 2024 to $33.4 billion, driven by organic sales growth of 7%. Amgen’s pipeline candidates, including Repatha and Tezspire, have shown promising results, providing a steady source of income for investors.
AbbVie, on the other hand, has maintained its dividend payments for an impressive 52 consecutive years. The company’s revenue growth was driven by its best-selling medicine Humira, which helped it achieve market-beating returns. Although Humira has lost its patent exclusivity, AbbVie’s pipeline of immunology products and other growth drivers have ensured continued success.
Both companies have a strong ability to develop and market blockbusters, which is their most important asset. Amgen offers a forward yield of 3%, while AbbVie provides a yield of 3.1%. Their cash payout ratios are also reasonable, giving them plenty of room to grow their dividends.
Investors seeking long-term income can trust these two companies to maintain their dividend programs for years to come.
Source: https://www.fool.com/investing/2025/03/07/2-dividend-stocks-to-buy-for-a-lifetime-of-passive